By Bill Anderson, FCCA, Chief Executive Officer, Assetica — 2026-06-23
UAE healthcare businesses trade at 6x to 10x EBITDA, among the highest of any sector. What drives that premium, and why physician dependence and insurance mix decide where a clinic lands in the range.
Barriers to entry are real: DHA, DoH or MoHAP licensing, facility approvals, insurance empanelment and clinical staffing all take time and capital to replicate. Demand is structural (mandatory insurance, growing population) and revenue is substantially payor-backed rather than discretionary. Add active consolidation by groups seeking scale, and profitable clinics attract 6x to 10x EBITDA where a comparable retail business would see half that.
A clinic whose revenue follows one or two named doctors is not a business; it is a practice, and buyers price it that way. The valuation tests what share of revenue is attached to individual clinicians, whether contracts and non-competes are enforceable, and how referrals arrive. Clinics that institutionalise demand through brand, insurance panels, corporate contracts and multi-practitioner teams hold the top of the range; single-rainmaker practices are discounted or structured as earn-outs.
In the UAE, the payor mix is the revenue quality. Buyers analyse the split across insurers, the share of rejected and resubmitted claims, average collection periods, and dependence on any single network agreement. Aged receivables and high rejection rates are valued as what they are: revenue that may never become cash. Cash-pay and corporate-contract revenue diversify the risk and support the multiple.
What is a UAE clinic worth?
Typically 6x to 10x normalised EBITDA, among the highest multiples in the UAE market, supported by licensing barriers, insured demand and consolidation appetite. Position within the range depends chiefly on physician dependence, payor mix and growth capacity.
How does physician dependence affect the price?
Decisively. If revenue follows named doctors, buyers discount the multiple or structure the price as an earn-out contingent on retention. Clinics with institutional demand, brand, insurance panels, corporate contracts and team-based care, command the premium.
How are insurance receivables treated?
As a quality-of-earnings question: buyers test rejection rates, resubmission cycles and aging. Receivables unlikely to collect are removed from working capital, and heavy dependence on a single insurer network is priced as concentration risk.